OUR PIPELINE

A new standard in radiation oncology

Through our lead product NBTXR3, we aim to help millions of patients fighting cancer worldwide by improving treatment outcomes without increasing harmful side effects. We believe that radiotherapy-activated NBTXR3 has the potential to become the global standard of care in the treatment of solid tumors.

NBTXR3 in the clinic

Patients (Current Study)

Phase I

Phase II

Phase III

Operational Sponsor

Milestone

Head & Neck

Elderly Cisplatin-ineligible (NANORAY-312, RT-R3 +/- cetuximab vs RT +/- cetuximab)

500

Phase I

Phase II

Phase III

Last Patient Recruited 1H26

R/M IO Naïve (Study 1100, RT-R3 fb anti-PD-1)

35+

Phase I

Phase II

Phase III

New Data 1H24

R/M IO Resistant (Study 1100, RT-R3 fb anti-PD-1)

35+

Phase I

Phase II

Phase III

New Data 1H24

R/M (MDA-0541, RT-R3 fb anti-PD-1)

Phase I

Phase II

Phase III

–

Lung

Inoperable, Stage 3

Phase I

Phase II

Phase III

First Patient Randomized

Inoperable, Recurrent (MDA-0123, Reirradiation RT-R3)

Phase I

Phase II

Phase III

First Data 1H25

Expansion Opportunities

Soft Tissue Sarcoma (Act.In.Sarc, RT-R3 fb resection)

180

Phase I

Phase II

Phase III

Completed

Rectal (Study 1001, RT-R3 concurrent CT)

Phase I

Phase II

Phase III

Completed

Advanced Solid (MDA-0618, RT-R3 with anti-PD-1)

Phase I

Phase II

Phase III

–

Cisplatin-eligible H&N (Study 1002, RT-R3 concurrent CT)

Phase I

Phase II

Phase III

Completed

HCC & Liver Mets (Study 103, RT-R3)

Phase I

Phase II

Phase III

Completed

Pancreas (MDA-1001, RT-R3)

Phase I

Phase II

Phase III

Updated Data 2H24

Esophageal (MDA-0122, RT-R3 concurrent CT)

Phase I

Phase II

Phase III

First Data FY25

IO Resistant Multiple Primary Tumors (Study 1100, RT-R3 fb anti-PD-1)

35+

Phase I

Phase II

Phase III

First Data FY25

Nanobiotix granted Janssen a worldwide license for the development and commercialization of NBTXR3 as announced July 10, 2023; On December 26, 2023, Nanobiotix announced that Janssen had assumed responsibility for operations in Asia after securing global rights to NBTXR3 in China and Other Asian markets from former Nanobiotix collaborator LianBio; Nanobiotix and Janssen have also aligned to intent to transfer the global sponsorship for NANORAY-312 as announced on May 21, 2024; IO Resistant Mets: Metastases from different primary tumors in IO resistant patients; RT-R3: RT activated NBTXR3; fb: followed by; CT: chemotherapy.

Clinical trials

Radiotherapy-activated NBTXR3 is currently being evaluated alone and in combination with other anticancer therapies in ongoing clinical trials that span an array of solid tumors. These trials evaluate the efficacy and safety of NBTXR3 in various cancer types and will provide important insights into the potential applications of it in clinical practice.